AIM ImmunoTech Resumes Trading on NYSE American
- Resumption of trading on a major U.S. exchange (NYSE American) enhances company visibility and trading accessibility
- Maintaining NYSE American listing indicates compliance with exchange requirements
- Previous trading suspension suggests potential compliance or regulatory issues that led to the halt
Company trading under the ticker 鈥淎IM鈥� NYSE American effective at the start of trading today, Tuesday, June 17th
OCALA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (鈥淎IM鈥� or the 鈥淐ompany鈥�) today announced that its common stock has resumed trading on the NYSE American under the symbol "AIM" and CUSIP 00901B303, effective at the start of trading today, June 17, 2025.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company鈥檚 lead product is a first-in-class investigational drug called Ampligen庐 (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit聽聽and connect with the Company on聽,听, and聽.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 鈥淧SLRA鈥�). Words such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渃ontinue,鈥� 鈥渂elieve,鈥� 鈥減otential,鈥� 鈥渦pcoming鈥� and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 [email protected]
FAQ
When did AIM ImmunoTech (AIM) resume trading on NYSE American?
What is AIM ImmunoTech's new ticker symbol and CUSIP on NYSE American?
Why was AIM ImmunoTech's stock previously suspended from trading?
What are the implications of AIM stock resuming trading on NYSE American?
